Abound Bio, Inc.

R&D Whiplash At GSK GSK plc CEO Emma Walmsley made her debut at J.P. Morgan five years ago, outlining an ambitious strategy to turn the company into an oncology powerhouse. That vision has not becom

After a string of failed drug candidates from its in-house R&D, Galapagos CEO Paul Stoffels has unveiled a new focus on immunology and oncology for the company, along with plans for more acquisition

Biopharma Acquisitions Biopharma merger and acquisition value for the second quarter of 2022 reached $25.4bn from 36 transactions, 20 of which had disclosed values. Four M&A transactions hit or exceed

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Junshi Gets Four Cancer Candidates From